JP2016503035A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503035A5 JP2016503035A5 JP2015548129A JP2015548129A JP2016503035A5 JP 2016503035 A5 JP2016503035 A5 JP 2016503035A5 JP 2015548129 A JP2015548129 A JP 2015548129A JP 2015548129 A JP2015548129 A JP 2015548129A JP 2016503035 A5 JP2016503035 A5 JP 2016503035A5
- Authority
- JP
- Japan
- Prior art keywords
- diamidine
- use according
- liver
- pentamidine
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YBVNFKZSMZGRAD-UHFFFAOYSA-N pentamidine isethionate Chemical class OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 YBVNFKZSMZGRAD-UHFFFAOYSA-N 0.000 claims description 70
- 208000019423 liver disease Diseases 0.000 claims description 25
- 206010027476 Metastases Diseases 0.000 claims description 13
- 210000004185 liver Anatomy 0.000 claims description 13
- 230000009401 metastasis Effects 0.000 claims description 13
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 10
- 229960004448 pentamidine Drugs 0.000 claims description 9
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 229960001624 pentamidine isethionate Drugs 0.000 claims description 7
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 239000007909 solid dosage form Substances 0.000 claims description 6
- 231100000419 toxicity Toxicity 0.000 claims description 6
- 230000001988 toxicity Effects 0.000 claims description 6
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 5
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 5
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 5
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 4
- HWURPQUPKQFGJI-UHFFFAOYSA-N [amino-[4-[5-[4-[amino(azaniumylidene)methyl]phenoxy]pentoxy]phenyl]methylidene]azanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(C(=[NH2+])N)=CC=C1OCCCCCOC1=CC=C(C(N)=[NH2+])C=C1 HWURPQUPKQFGJI-UHFFFAOYSA-N 0.000 claims description 4
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 4
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- 206010011732 Cyst Diseases 0.000 claims description 3
- 208000018565 Hemochromatosis Diseases 0.000 claims description 3
- 206010023126 Jaundice Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 208000031513 cyst Diseases 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 3
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 3
- 150000004985 diamines Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- RDYMFSUJUZBWLH-UHFFFAOYSA-N endosulfan Chemical class C12COS(=O)OCC2C2(Cl)C(Cl)=C(Cl)C1(Cl)C2(Cl)Cl RDYMFSUJUZBWLH-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229960004562 carboplatin Drugs 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 4
- 235000008191 folinic acid Nutrition 0.000 description 4
- 239000011672 folinic acid Substances 0.000 description 4
- 229960005277 gemcitabine Drugs 0.000 description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
- 229960001691 leucovorin Drugs 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- -1 ionizing radiation Chemical compound 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 238000011255 standard chemotherapy Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745011P | 2012-12-21 | 2012-12-21 | |
| US61/745,011 | 2012-12-21 | ||
| PCT/CA2013/051003 WO2014094176A1 (en) | 2012-12-21 | 2013-12-20 | Uses and methods for the treatment of liver diseases or conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016503035A JP2016503035A (ja) | 2016-02-01 |
| JP2016503035A5 true JP2016503035A5 (enExample) | 2017-02-02 |
| JP6370801B2 JP6370801B2 (ja) | 2018-08-08 |
Family
ID=50977490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015548129A Expired - Fee Related JP6370801B2 (ja) | 2012-12-21 | 2013-12-20 | 肝疾患または肝障害の治療のための使用および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9375411B2 (enExample) |
| EP (1) | EP2934501A4 (enExample) |
| JP (1) | JP6370801B2 (enExample) |
| KR (1) | KR20150126595A (enExample) |
| CN (1) | CN104968340A (enExample) |
| AU (1) | AU2013362755B2 (enExample) |
| BR (1) | BR112015014836A2 (enExample) |
| CA (1) | CA2894466A1 (enExample) |
| HK (1) | HK1216721A1 (enExample) |
| MX (1) | MX2015007945A (enExample) |
| RU (1) | RU2015126505A (enExample) |
| WO (1) | WO2014094176A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111225686A (zh) * | 2017-08-15 | 2020-06-02 | 普罗根尼蒂公司 | 使用可摄入装置释放免疫调节剂治疗炎性疾病 |
| JP7153734B2 (ja) | 2017-11-16 | 2022-10-14 | モンドレックス・インコーポレーテッド | モノアミジン及びジアミジンのエンド－エキソヌクレアーゼ阻害剤とエンド－エキソヌクレアーゼ活性を阻害する方法 |
| CN110478340A (zh) * | 2018-05-14 | 2019-11-22 | 复旦大学 | 喷他嘧啶羟乙基磺酸盐在制备肝癌药物方面的应用 |
| WO2021034727A1 (en) | 2019-08-16 | 2021-02-25 | Applied Molecular Transport Inc. | Compositions, formulations, and interleukin production and purification |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA388674A (en) * | 1940-05-14 | The B. F. Goodrich Company | Brake structure | |
| GB1288376A (enExample) | 1968-10-29 | 1972-09-06 | ||
| DE2833135A1 (de) | 1978-07-28 | 1980-02-07 | Henkel Kgaa | Verwendung von substituierten oligocarbamidinen als mikrobistatika sowie diese enthaltende antimikrobielle mittel |
| US5204113A (en) | 1987-04-09 | 1993-04-20 | Fisons Plc | Pharmaceutical compositions containing pentamidine |
| US5084480A (en) | 1987-11-06 | 1992-01-28 | Fujisawa Usa, Inc. | Pentamidine salts useful in the treatment of pneumocystis carinii pneumonia |
| US4853416A (en) | 1988-04-25 | 1989-08-01 | Fisons Corporation | Solutions of pentamidine |
| US5162361A (en) * | 1990-04-10 | 1992-11-10 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Method of treating diseases associated with elevated levels of interleukin 1 |
| DE4321444A1 (de) | 1993-06-28 | 1995-01-05 | Bernd Prof Dr Clement | Pharmazeutische Zubereitung |
| JPH08333324A (ja) | 1995-06-08 | 1996-12-17 | Terumo Corp | ベンゼン誘導体およびそれを含有する医薬製剤 |
| JP3540457B2 (ja) | 1995-09-11 | 2004-07-07 | テルモ株式会社 | 抗血栓性を賦与した医療用基材 |
| AU762523C (en) | 1998-11-10 | 2004-02-12 | Janssen Pharmaceutica N.V. | HIV replication inhibiting pyrimidines |
| US7884090B2 (en) | 1999-03-17 | 2011-02-08 | Ernest L. Bonner, Jr. | Compositions and methods for the treatment of arthritis |
| US7115665B1 (en) | 2000-11-16 | 2006-10-03 | Onocozyme Pharma, Inc. | Inhibitors of endo-exonuclease activity for treating cancer |
| US6569853B1 (en) * | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
| US6693125B2 (en) | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
| CA2459793A1 (en) | 2001-09-07 | 2003-08-28 | The Cleveland Clinic Foundation | Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases |
| US20040010045A1 (en) | 2001-09-07 | 2004-01-15 | Taolin Yi | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
| WO2003092616A2 (en) * | 2002-05-01 | 2003-11-13 | The Cleveland Clinic Foundation | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
| US20050054708A1 (en) | 2003-07-28 | 2005-03-10 | Nichols Matthew James | Combinations of drugs for the treatment of neoplasms |
| US7994225B2 (en) | 2004-03-17 | 2011-08-09 | Rempex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections |
| WO2005089738A2 (en) | 2004-03-17 | 2005-09-29 | Mpex Pharmaceuticals, Inc. | Use and administration of bacterial efflux pump inhibitors |
| WO2007001455A2 (en) | 2004-11-12 | 2007-01-04 | Mediquest Therapeutics, Inc. | Hydrophobic polyamine amides as potent lipopolysaccharide sequestrants |
| TW200719903A (en) | 2005-04-19 | 2007-06-01 | Combinatorx Inc | Compositions for the treatment of neoplasms |
| US7199267B1 (en) | 2005-10-21 | 2007-04-03 | Mediquest Therapeutics, Inc. | Recognition of oligiosaccaride molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases |
| US20070197658A1 (en) | 2006-02-22 | 2007-08-23 | David Sunil A | Polyamines and their use as antibacterial and sensitizing agents |
| US20080226596A1 (en) | 2006-06-19 | 2008-09-18 | Taolin Yi | Therapeutic compositions and methods useful in treating hepatitis |
| DE102008007426A1 (de) | 2008-02-01 | 2009-08-06 | Rheinische Friedrich-Wilhelms-Universität Bonn | Unbenetzbare Oberflächen |
| DE102008007381A1 (de) * | 2008-02-01 | 2009-08-13 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg | Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten |
| US8436049B2 (en) | 2008-02-21 | 2013-05-07 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Uses of pentamidine and related compounds |
| JP2012525371A (ja) * | 2009-05-01 | 2012-10-22 | オンコザイム・ファーマ・インコーポレイテッド | 癌を治療するためのペンタミジンの組み合わせ |
| WO2011035225A1 (en) | 2009-09-21 | 2011-03-24 | President And Fellows Of Harvard College | Synergistic combination therapy |
| US20130244963A1 (en) | 2010-09-30 | 2013-09-19 | Portola Pharmaceuticals, Inc. | Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide |
| SI2550963T1 (sl) * | 2011-07-25 | 2017-05-31 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg | Estri amidoksim karboksilne kisline pentamidina kot predzdravila in njihova uporaba kot zdravila |
| WO2014009592A1 (en) * | 2012-07-11 | 2014-01-16 | Waterbox Oy | Apparatus for providing rotating movement |
-
2013
- 2013-12-20 KR KR1020157019648A patent/KR20150126595A/ko not_active Withdrawn
- 2013-12-20 JP JP2015548129A patent/JP6370801B2/ja not_active Expired - Fee Related
- 2013-12-20 AU AU2013362755A patent/AU2013362755B2/en not_active Ceased
- 2013-12-20 HK HK16104784.4A patent/HK1216721A1/zh unknown
- 2013-12-20 CN CN201380067678.5A patent/CN104968340A/zh active Pending
- 2013-12-20 US US14/653,807 patent/US9375411B2/en not_active Expired - Fee Related
- 2013-12-20 MX MX2015007945A patent/MX2015007945A/es unknown
- 2013-12-20 RU RU2015126505A patent/RU2015126505A/ru not_active Application Discontinuation
- 2013-12-20 WO PCT/CA2013/051003 patent/WO2014094176A1/en not_active Ceased
- 2013-12-20 BR BR112015014836A patent/BR112015014836A2/pt not_active Application Discontinuation
- 2013-12-20 EP EP13865316.7A patent/EP2934501A4/en not_active Withdrawn
- 2013-12-20 CA CA2894466A patent/CA2894466A1/en not_active Abandoned
-
2016
- 2016-06-09 US US15/178,301 patent/US9827211B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507914A5 (enExample) | ||
| JP2010514787A5 (enExample) | ||
| WO2010121128A3 (en) | Compositions and methods for treating or inhibiting liver injury | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| JP2020514311A5 (enExample) | ||
| JP5767122B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| HK1198869A1 (en) | Combination treatments for hepatitis c | |
| JP2012502047A5 (enExample) | ||
| CO2022000016A2 (es) | Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd) | |
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| JP2015502926A5 (enExample) | ||
| JP2017529389A5 (enExample) | ||
| JP2016503035A5 (enExample) | ||
| JP2008514577A5 (enExample) | ||
| JP2016516773A5 (enExample) | ||
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| AR110800A1 (es) | MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA | |
| JP2015522603A5 (enExample) | ||
| JP2012511510A5 (enExample) | ||
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JP2018506533A5 (enExample) | ||
| JP2014534229A5 (enExample) |